Important Safety Update: Topiramate (Topamax)
The MHRA has introduced new safety measures for topiramate following a comprehensive review of its use in pregnancy. Topiramate is now contraindicated in pregnancy and in women of childbearing potential unless strict conditions are met.
Key Points
- Topiramate carries a significant risk of birth defects and developmental disorders when used during pregnancy
- A formal Pregnancy Prevention Programme is now mandatory for all women of childbearing potential prescribed this medication
- Healthcare providers must ensure patients understand the risks and confirm appropriate contraception is in place
- Existing patients on topiramate should be reviewed to ensure they meet the new safety criteria
Affected Medications
- Topiramate (all formulations and strengths)
- Topamax (branded product)
- All generic equivalents
Recommended Actions
- Prescribers: Review all women of childbearing potential currently on topiramate. Discuss risks, benefits, and contraception requirements. Consider alternative treatments where appropriate.
- Patients: Do not stop taking topiramate without speaking to your doctor. If you are planning pregnancy or may become pregnant, contact your healthcare provider immediately.
- All responders: Be aware of this contraindication when assessing patients on topiramate, particularly in pre-hospital and emergency settings.
Further Information
Read the full MHRA drug safety update on the UK government website.